Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue FactorBusiness Wire • 01/06/22
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell CarcinomaBusiness Wire • 01/05/22
Exelixis to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022Business Wire • 01/04/22
Exelixis (EXEL) Initiates Study on XL092 in Advanced Solid TumorsZacks Investment Research • 12/16/21
Exelixis Announces Initiation of Phase 1b Trial Evaluating XL092 in Combination with Immuno-oncology Therapies in Patients with Advanced Solid TumorsBusiness Wire • 12/15/21
Exelixis (EXEL) Down 14.8% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 12/02/21
Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer at ESMO Asia Virtual Oncology Week 2021Business Wire • 11/20/21
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung CancerBusiness Wire • 11/09/21
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November and DecemberBusiness Wire • 11/03/21
Exelixis, Inc. (EXEL) CEO Michael Morrissey on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/03/21
Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate UpdateBusiness Wire • 11/02/21
Wall Street Analysts Predict a 52% Upside in Exelixis (EXEL): Here's What You Should KnowZacks Investment Research • 10/26/21